Search results
Results from the WOW.Com Content Network
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 8.33% and 8.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for ...
One of the biggest stories of last week was how Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares plunged 21% in the...
The news lifted shares of Caribou more than 61% in early trade. Pfizer purchased nearly 4.7 million Caribou shares at $5.33 per share, Caribou said on Thursday, representing a premium of about 30% ...
About Caribou Biosciences, Inc. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies ...
Caribou is deploying the power of its chRDNA technology to carry out high efficiency multiple edits, to develop CRISPR-edited therapies. About Caribou Biosciences, Inc. Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases ...
Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases. Follow us @CaribouBio and visit www.cariboubio.com. Caribou Biosciences, Inc. contacts: Investors: Amy Figueroa, CFA investor.relations@cariboubio.com
Intellia Therapeutics was founded in November 2014 to develop biopharmaceuticals using CRISPR. [7] [8]It was backed by Atlas Venture and Novartis; the founding CEO was Nessan Bermingham from Atlas and the founding CSO was John Leonard, formerly CSO of AbbVie.
In 2011, Haurwitz and Doudna co-founded Caribou Biosciences, a gene editing spinout-startup company. [7] Haurwitz is the company's CEO and president. She holds several patents for CRISPR-based technologies. [5] The firm was initially housed in the basement of the building that housed Doudna's laboratory.